NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced updated results from the Phase 2 EPCORE ® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback